3.1. General characteristics
A total of 248 of 301 patients who were admitted to ICU with suspicion
of COVID-19 infection were included in the study. Of them, 37 (14.9%)
had NOAF (Figure 1). NOAF positive group was older than the NOAF
negative group (79.0 [71.5–84.0] vs 70.0 [60.0–78.0] years, p
< 0.001; Table 1).
The median duration from the onset of the COVID-19 infection symptoms to
NOAF development was 10.0 (5.0–17.0) days. The median duration from
hospitalization to NOAF development was 7.0 (2.0–12.5) days, and the
median duration from ICU admission to NOAF development was 3.0
(0.0–10.0) days.
Chronic obstructive pulmonary disease (COPD) (24.3% vs. 10.9%,
respectively; p = 0.03), and chronic kidney disease (CKD) (27.0%, vs.
13.3%, respectively; p = 0.046) were more common in the NOAF positive
group than the NOAF negative group. CCI median score was higher in the
NOAF positive group than the NOAF negative group as well (6.0
[5.0–7.0] vs. 4.0 [2.0–6.0], respectively, p = 0.003). NOAF
positive group had higher blood urea nitrogen (BUN) than the NOAF
negative group median values (37.1 [28.4–75.0] vs. 30.0
[21.0–50.0] mg/dL, respectively, p = 0.003).